Dementia-related psychosis data could make Acadia’s pimavanserin a blockbuster

Pivotal data reported late Wednesday support Acadia’s bid for a label expansion that would bring pimavanserin to the broader population of dementia-related psychosis and help allay safety concerns associated with a black box on the drug’s label.

Shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gained $6.20 (14%) to $50.48 Thursday, adding

Read the full 509 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers